Download PDF
Fortschr Neurol Psychiatr 2007; 75(6): 351-356
DOI: 10.1055/s-2006-944261
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Selektive Serotoninwiederaufnahmehemmer (SSRI) in der Behandlung von Paraphilien

Eine retrospektive StudieSelective Serotonine Reuptake Inhibitors (SSRI) in the Treatment of ParaphiliaA Retrospective StudyC.  Kraus1 , K.  Strohm1 , A.  Hill1 , N.  Habermann1 , W.  Berner1 , P.  Briken1
  • 1Institut für Sexualforschung und Forensische Psychiatrie (Direktor: Prof. Dr. med. W. Berner), Zentrum für Psychosoziale Medizin, Psychiatrie und Psychotherapie der Universität Hamburg (Direktor: Prof. Dr. med. D. Naber)
Further Information

Publication History

Publication Date:
10 October 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Neben antihormonellen Substanzen werden seit ca. 15 Jahren auch Selektive Serotoninwiederaufnahmehemmer (SSRI) zur Behandlung von Paraphilien eingesetzt. In dieser ersten, im deutschsprachigen Raum durchgeführten, offenen, unkontrollierten Studie wurden 16 ambulant mit einem SSRI und psychotherapeutisch behandelte, paraphile Patienten retrospektiv zu Symptomveränderungen und zur Behandlungszufriedenheit befragt. Es zeigte sich ein deutlicher Rückgang der paraphilen Symptomatik bei insgesamt hoher Behandlungszufriedenheit, trotz relativ häufig berichteter unerwünschter Medikamentenwirkungen. Die medikamentöse Behandlung mit SSRI stellt eine wichtige Ergänzung in der Behandlung paraphiler Patienten, insbesondere mit sog. „Hands-off”-Delikten dar.

Abstract

For about 15 years selective serotonine reuptake inhibitors (SSRI) have been used in the treatment of paraphilias. In an open, uncontrolled, retrospective study, which was the first in the German speaking countries we investigated 16 male outpatients, who have been treated for different paraphilias with SSRI and psychotherapy. There was a marked reduction in paraphilic symptoms. Despite high rates of sexual side effects most patients reported a high overall treatment satisfaction. SSRI are an important addition in pharmacological treatment of paraphilic patients, especially with a risk of so called “hands-off” delinquency.

Schlüsselwörter

Paraphilien - Pädophilie - Sexualstraftäter - SSRI - Pharmakotherapie

Key words

paraphilias - pedophilia - sex offender - SSRI - pharmacotherapy

Literatur

  • 1 Kafka M P, Hennen J. The paraphilia-related disorders: an empirical investigation of nonparaphilic hypersexuality disorders in outpatient males.  J Sex Marital Ther. 1999;  25 305-319
    Google Scholar
  • 2 Briken P, Berner W, Noldus J, Nika E, Michl U. Therapie mit dem LHRH-Agonisten Leuprorelinacetat bei Paraphilien und sexuell aggressiven Impulshandlungen.  Nervenarzt. 2000;  71 380-385
    CrossrefPubMedGoogle Scholar
  • 3 Briken P, Nika E, Berner W. Treatment of paraphilia with luteinizing hormone-releasing hormone agonists.  J Sex Marital Ther. 2001;  27 45-55
    CrossrefPubMedGoogle Scholar
  • 4 Briken P, Hill A, Berner W. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review.  J Clin Psychiat. 2003;  64 890-897
    Google Scholar
  • 5 Bianchi M. Fluoxetine-treatment of exhibitionism (letter).  Am J Psychiat. 1990;  147 1089-1090
    PubMedGoogle Scholar
  • 6 Lorefice L S. Fluoxetine-treatment of a fetish (letter).  J Clin Psychiat. 1991;  52 41
    PubMedGoogle Scholar
  • 7 Perilstein R D, Lipper S, Friedmann L J. Three cases of paraphilia responsive to fluoxetine-treatment.  J Clin Psychiat. 1991;  52 169-170
    PubMedGoogle Scholar
  • 8 Zohar J, Kaplan Z, Benjamin J. Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study.  J Clin Psychiat. 1994;  55 86-88
    PubMedGoogle Scholar
  • 9 Coleman E, Cesnik J, Moore A M, Dwyer S M. An exploratory study of the role of psychotropic medications in treatment of sexual offenders.  J Offender Rehabil. 1992;  18 75-88
    PubMedGoogle Scholar
  • 10 Kafka M P. Sertralin pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial.  Ann Clin Psychiat. 1994;  6 189-195
    PubMedGoogle Scholar
  • 11 Kafka M P, Prentky R A. Fluoxetine-treatment of nonparaphilic sexual addictions and paraphilias in men.  J Clin Psychiat. 1992;  53 351-358
    PubMedGoogle Scholar
  • 12 Bradford J MW. The treatment of sexual deviation using a pharmacological approach.  J Sex Res. 2000;  37 248-257
    PubMedGoogle Scholar
  • 13 Bradford J MW, Greenberg D M. Pharmacological treatment of deviant sexual behaviour.  Ann Rev Sex Res. 1996;  7 283-306
    PubMedGoogle Scholar
  • 14 Gijs I, Gooren L. Hormonal and psychopharmacological interventions in the treatment of paraphilias: An update.  J Sex Res. 1996;  33 273-290
    PubMedGoogle Scholar
  • 15 Greenberg D M, Bradford J MW. Treatment of the paraphilia disorders: A review of the role of selective serotonin reuptake inhibitors.  Sexual Abuse. 1997;  9 349-361
    PubMedGoogle Scholar
  • 16 Greenberg D M, Bradford J MW, Curry S, O'Rourke A B. A comparison of treatment of paraphilias with three serotonin reuptake inhibitors. A retrospective study.  Bull Am Acad Psychiat & Law. 1996;  24 525-532
    PubMedGoogle Scholar
  • 17 Rösler A, Witztum E. Pharmacotherapy of the paraphilias in the next millenium.  Behav Sci Law. 2000;  18 43-56
    PubMedGoogle Scholar
  • 18 Meston C M, Frohlich P F. The neurobiology of sexual function.  Arch Gen Psychiat. 2000;  57 1012-1030
    Google Scholar
  • 19 Waldinger M D, Berendsen H H, Blok B F, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation. The involvement of the serotonergic system.  Behav Brain Res. 1998;  92 111-118
    CrossrefPubMedGoogle Scholar
  • 20 Mendels J, Camera A, Sikes C. Sertraline treatment for premature ejaculation.  J Clin Psychopharm. 1995;  15 341-346
    CrossrefPubMedGoogle Scholar
  • 21 Coleman E, Gratzer T, Nesvacil L, Raymond N C. Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: A retrospective study.  J Clin Psychiat. 2000;  61 282-284
    PubMedGoogle Scholar
  • 22 Kafka M P, Hennen J. Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series.  J Clin Psychiat. 2000;  61 664-670
    PubMedGoogle Scholar
  • 23 Coccaro E F, Kavoussi R J. Fluoxetine and impulsive agressive behavior in personality-disordered subjects.  Arch Gen Psychiat. 1997;  54 1081-1088
    PubMedGoogle Scholar
  • 24 Virkkunen M, Dejong J, Bartko J, Linnoila M. Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters: a follow-up study.  Arch Gen Psychiat. 1989;  46 600-603
    PubMedGoogle Scholar
  • 25 Virkkunen M, Rawlings R, Tokola R, Poland R E, Guidotti A, Nemeroff C, Bissette G, Kalogeras K, Karonen S L, Linnoila M. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers.  Arch Gen Psychiat. 1994;  51 20-27
    PubMedGoogle Scholar
  • 26 Olivier B. Serotonergic mechanisms in aggression.  Novartis Found Symp. 2005;  268 171-183
    PubMedGoogle Scholar
  • 27 Berner W, Hill A, Briken P, Kraus C. Störungen der Sexualpräferenz - Paraphilien. In: Kockott G, Fahrner E-M (Hrsg.). Sexualstörungen. Stuttgart, New York: Thieme Verlag 2004: 107-152
    Google Scholar
  • 28 Stein D J, Hollander E, Anthony D T, Schneider F R, Fallon B A, Leibowitz M R, Klein D F. Serotonergic medications for sexual obsessions, sexual addiction and paraphilias.  J Clin Psychiat. 1992;  53 267-271
    PubMedGoogle Scholar
  • 29 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. 5. Auflage. Heidelberg: Springer-Verlag 2005
    Google Scholar

Dr. med. Christian Kraus

Universitätskrankenhaus Hamburg-Eppendorf Klinik für Psychiatrie und Psychotherapie, Station 1

Martinistr. 52

20246 Hamburg

Email: kraus@uke.uni-hamburg.de